New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and ...

At the recent American Society of Hematology (ASH) annual meeting, late-breaking phase III data demonstrated that adding tafasitamab (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

The FDA has granted accelerated approval for a subcutaneous (SC) formulation of mosunetuzumab (Lunsumio VELO, Roche) for the treatment of certain adults with relapsed or refractory follicular lymphoma ...

Thanks to a clinical trial for follicular lymphoma at MSK, Michael is able to spend time with family, including his granddaughter, Natalia. Retired New York City police officer Michael T. had grown ...

SAN DIEGO — Despite its significantly higher acquisition costs, lisocabtagene maraleucel (liso-cel, Breyanzi) demonstrated better survival and quality of life as well as fewer time toxicity challenges ...

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma. The FDA has granted Bristol Myers Squibb’s ...

(a) The smear is composed of blood only (smear, Diff-Quik stain). (b) The smear shows foamy macrophages and degenerated cyst fluid, with no follicular cells (smear, Diff-Quik stain). (c) Scant ...